Overview

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

Status:
Recruiting

Trial end date:
2026-07-27

Target enrollment:

Participant gender:

Summary

This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Wuhan Union Hospital, China

Collaborator:

Guangzhou Bio-gene Technology Co., Ltd

Treatments:

Cyclophosphamide
Fludarabine